CGAS and metabolic dysfunction-associated steatohepatitis: Could we treat both diseases by inhibiting the activation of the cGAS-STING pathway, especially in patients with psoriatic relapses with or without the conversion of steatohepatitis to nonalcoholic steatohepatitis?